Amendments to the Claims

Listing of Claims:

1. (Original) Use of N-benzoyl-staurosporine in the manufacture of a medicament for the; treatment of diabetic retinopathy with reduced hepatotoxicity in a selected patient population, where in the patient population is selected on the basis of the genotype of the patients at an *IL1A* genetic locus predictive of hepatotoxicity.

2. (Original) A method for predicting hepatotoxicity in a subject, comprising the steps of:

(a) obtaining the genotype of a subject at an *IL1A* genetic locus predictive of hepatotoxicity following administration of a staurosporine derivative; and

(b) determining whether the subject is at risk for hepatotoxicity following administration of the staurosporine derivative.

3. (Original) The method of claim 2, wherein the *IL1A* genetic locus is PG locus ID 279.

4. (Original) The method of claim 3, wherein a CC genotype at the PG locus ID 279 is predictive of a high risk of hepatotoxicity.

5. (Original) The method of claim 3, wherein a CT or TT genotype at the PG locus ID 279 is predictive of a low or average risk of hepatotoxicity.

6. (Original) The method of claim 2, wherein the *IL1A* genetic locus is PG locus ID 302.

7. (Original) The method of claim 6, wherein a GG genotype at the PG locus ID 302 is predictive of a high risk of hepatotoxicity.

8. (Original) The method of claim 6, wherein a GT or TT genotype at the PG locus ID 302 is predictive of a low or average risk of hepatotoxicity.

9. (Original) An improved method for treating a diabetic condition with at staurosporine derivative, comprising the steps of:

(a) obtaining the genotype of a subject to be treated at an *IL1A* genetic locus predictive of hepatotoxicity following administration of the staurosporine derivative;

(b) administering the staurosporine derivative to the subject.

10. (Original) A method for choosing a subject for inclusion in a clinical trial for determining the efficacy of treatment with a staurosporine derivative, comprising the steps of:

(a) obtaining the genotype of a subject at an *IL1A* genetic locus predictive of hepatotoxicity following administration of a staurosporine derivative; and

(b) then:

(i) including the subject in the trial if the genotype indicates a low or average risk of hepatotoxicity; or

(ii) excluding the subject from the trial if the genotype indicates a high risk of hepatotoxicity.

11. (Original) A kit or use in predicting hepatotoxicity, comprising:

(a) a reagent for detecting a genetic polymorphism in the *IL1A* gene that is biomarker of staurosporine derivative-mediated hepatotoxicity;

(b) a container for the reagent; and

(c) a written product on or in the container describing the use of the biomarker in predicting staurosporine derivative-mediated hepatotoxicity in subjects.

12. (Original) The kit of claim 11, wherein the *IL1A* genetic locus is PG locus ID 279.

13. (Original) The kit of claim 11, wherein the *IL1A* genetic locus is PG locus 1D 302.

14. (Original) The kit of claim 11, wherein the reagent is a set of primer pairs that hybridize to a polynucleotide on either the side of the genetic polymorphism and which define a nucleotide region that spans the genetic polymorphism.